The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats

International Journal of Neuroscience

Volumn 118, Issue 1, 2008, Pages 39-57

  Nakai, Satoru ^a   Hirose, Tsuyoshi ^a   Mori, Toyoki ^a   Stark, Arlene ^b   Araki, Hiroaki ^c   Kikuchi, Tetsuro ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b BRISTOL MYERS SQUIBB   (United States)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antipsychotic; Aripiprazole; Dopamine D2 receptor partial agonist; Prepulse inhibition; Schizophrenia; Startle response

Indexed keywords

7 [3 [4 (2,3 DIMETHYLPHENYL) 1 PIPERAZINYL]PROPOXY] 2(1H) QUINOLINONE; APOMORPHINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PRECLAMOL; QUETIAPINE; RISPERIDONE; TERGURIDE;

ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; MALE; NONHUMAN; PREPULSE INHIBITION; RAT; STARTLE REFLEX;

ACOUSTIC STIMULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; CONDITIONING, CLASSICAL; DOPAMINE AGENTS; DRUG INTERACTIONS; INHIBITION (PSYCHOLOGY); ION CHANNEL GATING; MALE; NEURAL INHIBITION; PIPERAZINES; QUINOLONES; RATS; RATS, WISTAR; REACTION TIME; RECEPTORS, DOPAMINE D2; STARTLE REACTION;

EID: 36448981025     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.1080/00207450601041989     Document Type: Article

References (34)

1. Bakshi, V. P., & Geyer, M. A. (1998). Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. Journal of Neuroscience, 18(20), 8394-8401.
2. Benkert, O., Muller-Siecheneder, F., & Wetzel, H. (1995). Dopamine agonists in schizophrenia: A review. European Neuropsychopharmacology, 5(Suppl), 43-53.
3. Bowles, T.M., & Levin, G.M. (2003). Aripiprazole: A new atypical antipsychotic drug. Annals Pharmacotherapy, 37(5), 687-694.
4. Braff, D., Stone, C., Callaway, E., Geyer, M., Glick, I., & Bali, L. (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology, 15(4), 339-343.
5. Braff, D. L., & Geyer, M. A. (1990). Sensorimotor gating and schizophrenia. Human and animal model studies. Archives of General Psychiatry, 47(2), 181-188.
6. Braff, D. L., Swerdlow, N. R., & Geyer, M. A. (1999). Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. American Journal of Psychiatry, 156(4), 596-602.
7. Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics, 302(1), 381-389.
8. Cadenhead, K. S., Geyer, M. A., & Braff, D. L. (1993). Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. American Journal of Psychiatry, 150(12), 1862-1867.
9. Cadenhead, K. S., Swerdlow, N. R., Shafer, K. M., Diaz, M., & Braff, D. L. (2000). Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: Evidence of inhibitory deficits. American Journal of Psychiatry, 157(10), 1660-1668.
10. Clark, D., Hjorth, S., & Carlsson, A. (1985). Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. Journal of Neural Transmission, 62(3-4), 171-207.
11. Cornblatt, B., Kern, R. S., Carson, W. H., Ali, M. W., Luo, X., & Green, M. (2002). Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. International Journal of Neuropsychopharmacology, 5(Suppl 1), S185.
12. Davis, M. (1980). Neurochemical modulation of sensory-motor reactivity: Acoustic and tactile startle reflexes. Neuroscience and Biobehavioral Reviews, 4(2), 241-263.
13. Dirks, A., Groenink, L., Westphal, K. G., Olivier, J. D., Verdouw, P. M., Van Der Gugten, J., Geyer, M. A., & Olivier, B. (2003). Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs. Neuropsychopharmacology, 28(10), 1790-1798.
14. Duncan, E., Szilagyi, S., Schwartz, M., Kunzova, A., Negi, S., Efferen, T., Peselow, E., Chakravorty, S., Stephanides, M., Harmon, J., Bugarski-Kirola, D., Gonzenbach, S., & Rotrosen, J. (2003). Prepulse inhibition of acoustic startle in subjects with schizophrenia treatedwith olanzapine or haloperidol. Psychiatry Research, 120(1), 1-12.
15. Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berlin), 156, 117-154.
16. Johansson, C., Jackson, D. M., Zhang, J., & Svensson, L. (1995). Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: Effects of antipsychotics and other agents in rats. Pharmacology, Biochemistry, and Behavior, 52(4), 649-654.
17. Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry, 63(9), 763-771.
18. Kasper, S., Lerman, M. N.,McQuade,R.D., Saha,A., Carson, W. H.,Ali, M.,Archibald, D., Ingenito,G., Marcus,R.,&Pigott, T. (2003). Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. International Journal of Neuropsychopharmacology, 6(4), 325-337.
19. Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995). 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. Journal of Pharmacology and Experimental Therapeutics, 274(1), 329-336.
20. Lahti, A. C., Weiler, M. A., Corey, P. K., Lahti, R. A., Carlsson, A., & Tamminga, C. A. (1998). Antipsychotic properties of the partial dopamine agonist (-)-3-(3- hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biological Psychiatry, 43(1), 2-11.
21. Mackeprang, T., Kristiansen, K. T., & Glenthoj, B. Y. (2002). Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biological Psychiatry, 52(9), 863-873.
22. Mansbach, R. S., Geyer, M. A., & Braff, D. L. (1988). Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berlin), 94(4), 507-514.
23. Olbrich, R., & Schanz, H. (1991). An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. Journal of Neural Transmission. General Section, 84(3), 233-236.
24. Pigott, T. A., Carson, W. H., Saha, A. R., Torbeyns, A. F., Stock, E. G., & Ingenito, G. G. (2003). Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study. Journal of Clinical Psychiatry, 64(9), 1048-1056.
25. Potkin, S.G., Saha,A. R.,Kujawa,M. J., Carson, W. H.,Ali, M., Stock, E., Stringfellow, J., Ingenito,G.,&Marder, S. R. (2003).Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry, 60(7), 681-690.
26. Rigdon, G. C. (1990). Differential effects of apomorphine on prepulse inhibition of acoustic startle reflex in two rat strains. Psychopharmacology (Berlin), 102(3), 419-421.
27. Svensson, K., Ekman, A., Piercey, M. F., Hoffmann, W. E., Lum, J. T., & Carlsson, A. (1991). Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn-Schmiedeberg's Archives of Pharmacology, 344(3), 263-274.
28. Svensson, L. (1990). The role of the dopaminergic system in the modulation of the acoustic startle response in the rat. European Journal of Pharmacology, 175(1), 107-111.
29. Swerdlow, N. R., Braff, D. L., Geyer, M. A., & Koob, G. F. (1986). Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biological Psychiatry, 21(1), 23-33.
30. Swerdlow, N. R., Geyer, M. A., & Braff, D. L. (2001). Neural circuit regulation of prepulse inhibition of startle in the rat: Current knowledge and future challenges. Psychopharmacology (Berlin), 156, 194-215.
31. Swerdlow, N. R., Varty, G. B., & Geyer, M. A. (1998). Discrepant findings of clozapine effects on prepulse inhibition of startle: Is it the route or the rat Neuropsychopharmacology, 18(1), 50-56.
32. Tadori, Y., Miwa, T., Tottori, K., Burris, K. D., Stark, A., Mori, T., & Kikuchi, T. (2005). Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European Journal of Pharmacology, 515(1-3), 10-19.
33. Tamminga, C. A. (2002). Partial dopamine agonists in the treatment of psychosis. Journal of Neural Transmission, 109(3), 411-420.
34. Varty, G. B., & Higgins, G. A. (1995). Examination of drug-induced and isolationinduced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology (Berlin), 122(1), 15-26.